- Welcome to Ryan's District Boards.
Posted by wlsqfjaru
- March 09, 2011, 03:25:24 AM,You are not allowed to view links.
Register or Login
Tirofiban in elderly patients with acute coronary syndrome clinical observation
Proof of tirofiban in patients with UAP and the therapeutic value of NSTEAMI ¨, but the occurrence of fatal bleeding, especially bleeding adverse reactions is still an important issue,You are not allowed to view links. Register or Login, another elderly patients with ACS because of the merger more other diseases and cardiovascular risk factors, for Law of non-class safety and effectiveness of how the concern H. Tirofiban is a potent GPIIb / ma receptor antagonist, which by the selective receptor binding and platelet membrane GPI1b/IIIa occupy its binding site on that GPIIb / ma receptor can not clotting factor I binding, thus inhibiting platelet aggregation. Tirofiban on various stimuli-induced platelet aggregation are valid, the inhibition and dose proportional. In this study, elderly patients with ACS have higher combined risk factors for disease and cardiovascular disease in elderly patients with ACS application of platelet glycoprotein Ⅱ b / IIIa receptor antagonists increased risk of bleeding, mainly skin and mucous membrane bleeding, and are not serious bleeding events. Hospitalization and follow-up period of 1 month major adverse cardiac events was 9.7%, mainly recurrent angina rehospitalization,You are not allowed to view links. Register or Login, myocardial infarction and death in 1 case, suggesting that tirofiban pump for 24 to 48 hours with good people Recent effectiveness. This study shows that elderly patients with ACS tirofiban are likely to increase despite the slight bleeding, but not associated with thrombocytopenia and the increase in severe bleeding,You are not allowed to view links. Register or Login, and can reduce near-term major adverse cardiovascular events in elderly patients with good safety and effectiveness, but it is worth noting that careful screening of patients before treatment,You are not allowed to view links. Register or Login, while medication is necessary to strengthen the hemoglobin, platelet count and clinical monitoring of bleeding.
Tirofiban in elderly patients with acute coronary syndrome clinical observation
Proof of tirofiban in patients with UAP and the therapeutic value of NSTEAMI ¨, but the occurrence of fatal bleeding, especially bleeding adverse reactions is still an important issue,You are not allowed to view links. Register or Login, another elderly patients with ACS because of the merger more other diseases and cardiovascular risk factors, for Law of non-class safety and effectiveness of how the concern H. Tirofiban is a potent GPIIb / ma receptor antagonist, which by the selective receptor binding and platelet membrane GPI1b/IIIa occupy its binding site on that GPIIb / ma receptor can not clotting factor I binding, thus inhibiting platelet aggregation. Tirofiban on various stimuli-induced platelet aggregation are valid, the inhibition and dose proportional. In this study, elderly patients with ACS have higher combined risk factors for disease and cardiovascular disease in elderly patients with ACS application of platelet glycoprotein Ⅱ b / IIIa receptor antagonists increased risk of bleeding, mainly skin and mucous membrane bleeding, and are not serious bleeding events. Hospitalization and follow-up period of 1 month major adverse cardiac events was 9.7%, mainly recurrent angina rehospitalization,You are not allowed to view links. Register or Login, myocardial infarction and death in 1 case, suggesting that tirofiban pump for 24 to 48 hours with good people Recent effectiveness. This study shows that elderly patients with ACS tirofiban are likely to increase despite the slight bleeding, but not associated with thrombocytopenia and the increase in severe bleeding,You are not allowed to view links. Register or Login, and can reduce near-term major adverse cardiovascular events in elderly patients with good safety and effectiveness, but it is worth noting that careful screening of patients before treatment,You are not allowed to view links. Register or Login, while medication is necessary to strengthen the hemoglobin, platelet count and clinical monitoring of bleeding.